Vanda Pharmaceuticals Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P dip, trading choppy as tech stocks fall
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 9c
November 3, 2015 5:26 PM ESTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of ($0.11), $0.09 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $28.3 million versus the consensus estimate of $28.84 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
... More